Urinary Bladder Neoplasms

The supplied literature supports bladder cancer as multifactorial, with advanced age, male sex, cigarette smoking, and broader external exposures contributing to development. It also notes that genetic factors are part of the disease literature, but no specific causal mutation or single cause is established in the grounding.

The disease includes biologically distinct non-muscle-invasive and muscle-invasive forms with unique pathological and molecular characteristics. The grounding also points to genetic drivers, luminal and basal molecular subtypes, and tumor microenvironment involvement, indicating that tumor biology and immune context contribute to progression and treatment response.

Advanced age, male sex, and cigarette smoking are explicitly identified risk factors. The epidemiology review also indicates that external risk factors and the wider exposome contribute significantly, but the supplied grounding does not specify additional individual exposures.

Non-muscle-invasive bladder cancer is generally managed with transurethral resection of the bladder tumor followed by risk-stratified intravesical therapy, including intravesical immunotherapy such as BCG. Advanced or metastatic disease is treated with systemic therapy, including platinum-based chemotherapy, immune checkpoint inhibitors, and antibody-drug conjugates; the grounding specifically includes cisplatin, pembrolizumab, nivolumab, and enfortumab vedotin as co-studied therapies.